Bone disease in β thalassemia patients: past, present and future perspectives
Tóm tắt
Từ khóa
Tài liệu tham khảo
Thein, 2013, The molecular basis of β-thalassemia, Cold Spring Harb Perspect Med, 3, a011700, 10.1101/cshperspect.a011700
Weatherall, 2008, Hemoglobinopathies worldwide: present and future, Curr Mol Med, 8, 592, 10.2174/156652408786241375
Kountouris, 2014, IthaGenes: an interactive database for haemoglobin variations and epidemiology, PLoS One, 9, e103020, 10.1371/journal.pone.0103020
De Sanctis, 2017, β-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint, Mediterr J Hematol Infect Dis, 9, e2017018, 10.4084/mjhid.2017.018
Musallam, 2012, β-thalassemia intermedia: a clinical perspective, Cold Spring Harb Perspect Med, 2, a013482, 10.1101/cshperspect.a013482
Taher, 2010, Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study, Blood, 115, 1886, 10.1182/blood-2009-09-243154
Cazzola, 1995, Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major, Br J Haematol, 89, 473, 10.1111/j.1365-2141.1995.tb08351.x
Haidar, 2010, Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia, Eur Spine J, 19, 871, 10.1007/s00586-010-1357-2
De Sanctis, 2016, Clinical and biochemical data of adult thalassemia major patients (TM) with multiple endocrine complications (MEC) versus TM patients with normal endocrine functions: a long-term retrospective study (40 years) in a tertiary Care Center in Italy, Mediterr J Hematol Infect Dis, 8, e2016022, 10.4084/mjhid.2016.022
Scacchi, 2016, Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins, Endocrine, 53, 551, 10.1007/s12020-016-0865-1
Baldini, 2014, Beta-thalassaemia intermedia: evaluation of endocrine and bone complications, Biomed Res Int, 2014, 174581, 10.1155/2014/174581
De Sanctis, 2013, Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment, Pediatr Endocrinol Rev, 11, 167
Dede, 2016, Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease, Osteoporos Int, 27, 3409, 10.1007/s00198-016-3719-z
Chatterjee, 2012, Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome, Br J Haematol, 159, 462, 10.1111/bjh.12048
Dines, 1976, Fractures in thalassemia, J Bone Joint Surg Am, 58, 662, 10.2106/00004623-197658050-00014
Exarchou, 1984, Fractures and epiphyseal deformities in beta-thalassemia, Clin Orthop, 189, 229, 10.1097/00003086-198410000-00024
Finsterbush, 1985, Fracture patterns in thalassemia, Clin Orthop, 192, 132, 10.1097/00003086-198501000-00017
Bedair, 2008, Review of radiologic skeletal changes in thalassemia, Pediatr Endocrinol Rev, 6, 123
De Sanctis, 2013, Growth and endocrine disorders in thalassemia: the international network on endocrine complications in thalassemia (I-CET) position statement and guidelines, Indian J Endocrinol Metab, 17, 8, 10.4103/2230-8210.107808
Angelopoulos, 2007, Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major, J Bone Miner Metab, 25, 60, 10.1007/s00774-006-0728-6
Morabito, 2004, Osteoprotegerin and RANKL in the pathogenesis of thalassemia induced osteoporosis: new pieces of the puzzle, J Bone Miner Res, 19, 722, 10.1359/jbmr.040113
Morabito, 2007, The “lively” cytokines network in β-thalassaemia major-related osteoporosis, Bone, 40, 1588, 10.1016/j.bone.2007.02.020
Oztürk, 2001, Increased plasma levels of interleukin-6 and interleukin-8 in beta-thalassaemia major, Haematologia (Budap), 31, 237, 10.1163/15685590152763782
Baldini, 2014, Thalassemic osteopathy: a new marker of bone deposition, Blood Cells Mol Dis, 52, 91, 10.1016/j.bcmd.2013.09.008
Voskaridou, 2009, Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration, Haematologica, 94, 725, 10.3324/haematol.2008.000893
Voskaridou, 2012, High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density, Horm Metab Res, 44, 909, 10.1055/s-0032-1312618
Wonke, 1998, Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major, J Pediatr Endocrinol Metab, 11, 795
Ferrara, 2002, Effect of VDR polymorphisms on growth and bone mineral density in homozygous beta thalassaemia, Br J Haematol, 117, 436, 10.1046/j.1365-2141.2002.03426.x
Perrotta, 2000, Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background, Br J Haematol, 111, 461
Langdahl, 2003, Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis, Bone, 32, 297, 10.1016/S8756-3282(02)00971-7
Cong, 2016, A single nucleotide polymorphism in the TGF-β1 gene (rs1982073 C>T) may contribute to increased risks of bone fracture, osteoporosis, and osteoarthritis: a meta-analysis, Clin Rheumatol, 35, 973, 10.1007/s10067-014-2840-7
Ragab, 2016, Evaluation of glutathione-S-transferase P1 polymorphism and its relation to bone mineral density in Egyptian children and adolescents with Beta-thalassemia major, Mediterr J Hematol Infect Dis, 8, e2016004, 10.4084/mjhid.2016.004
Elhoseiny, 2016, Vitamin D receptor (VDR) gene polymorphisms (FokI, BsmI) and their relation to vitamin D status in pediatrics βeta thalassemia major, Indian J Hematol Blood Transfus, 32, 228, 10.1007/s12288-015-0552-z
Dimitriadou, 2011, Fok-I gene polymorphism of vitamin D receptor in patients with beta-thalassemia major and its effect on vitamin D status, Hematology, 16, 54, 10.1179/102453311X12902908411878
Douglaraki, 2012, Bone health evaluation of children and adolescents with homozygous β-thalassemia:Implcations for practice, J Pediatr Hematol Oncol, 34, 344, 10.1097/MPH.0b013e3182431ddb
Hapgood, 2015, Erythropoiesis is not equally suppressed in transfused males and females with β-thalassemia major: are there clinical implications?, Haematologica, 100, e292
Taher, 2015, When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia, Vox Sang, 108, 1, 10.1111/vox.12201
Kattamis, 1982, The clinical phenotype of β and δβ thalassemias in Greece, Eur J Pediatr, 139, 135, 10.1007/BF00441497
Musallam, 2011, Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia, Haematologica, 96, 1605, 10.3324/haematol.2011.047852
Yamasaki, 2009, Excess iron inhibits osteoblast metabolism, Toxicol Lett, 191, 211, 10.1016/j.toxlet.2009.08.023
De Vernejoul, 1984, Effects of iron overload on bone remodeling in pigs, Am J Pathol, 116, 377
Mahachoklertwattana, 2003, Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron associated focal osteomalacia, J Clin Endocrinol Metab, 88, 3966, 10.1210/jc.2002-021548
Kim, 2012, Iron overload accelerates bone loss in healthy postmenopausal women and middle-aged men: a 3 year retrospective longitudinal study, J Bone Miner Res, 27, 2279, 10.1002/jbmr.1692
Levin, 1995, MRI marrow observations in thalassemia: the effects of the primary disease, transfusional therapy, and chelation, Pediatr Radiol, 25, 607, 10.1007/BF02011827
Hoffbrand, 2012, How I treat transfusional iron overload, Blood, 120, 3657, 10.1182/blood-2012-05-370098
Wonke, 1998, Combined therapy with deferiprone and desferrioxamine, Br J Haematol, 103, 361, 10.1046/j.1365-2141.1998.01002.x
De Sanctis, 1996, Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine, Eur J Pediatr, 155, 368, 10.1007/BF01955263
De Sanctis, 2000, Osteochondrodystrophic lesions in chelated thalassemic patients: an histological analysis, Calcif Tissue Int, 67, 134, 10.1007/s00223001121
Sharma, 2013, Distal ulnar changes in children with thalassemia and deferiprone related arthropathy, Pediatr Blood Cancer, 60, 1957, 10.1002/pbc.24678
Wong, 2016, Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria, Bone, 85, 55, 10.1016/j.bone.2016.01.011
Yacobovich, 2010, Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox, J Pediatr Hematol Oncol, 32, 564, 10.1097/MPH.0b013e3181ec0c38
Milat, 2012, A case of hypophosphatemic osteomalacia secondary to deferasirox therapy, J Bone Miner Res, 27, 219, 10.1002/jbmr.522
Cappellini, 2014
Voskaridou, 2001, Bone resorption is increased in young adults with thalassaemia major, Br J Haematol, 112, 36, 10.1046/j.1365-2141.2001.02549.x
Anapliotou, 1995, The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches, Clin Endocrinol (Oxf), 42, 279, 10.1111/j.1365-2265.1995.tb01876.x
Chatterjee, 2011, Use of hormone replacement therapy for correction of high turnover bone disease in hypogonadal β-thalassemia major patients presenting with osteoporosis: comparison with idiopathic premature ovarian failure, Hemoglobin, 35, 653, 10.3109/03630269.2011.630120
Soliman, 1998, GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with beta-thalassaemia, Eur J Endocrinol, 138, 394, 10.1530/eje.0.1380394
Soliman, 1999, Spontaneous and provoked growth hormone (GH) secretion and insulin-like growth factor I (IGF-I) concentration in patients with beta thalassaemia and delayed growth, J Trop Pediatr, 45, 327, 10.1093/tropej/45.6.327
Soliman, 2009, Growth and factors affecting it in thalassemia major, Hemoglobin, 33, S116, 10.3109/03630260903347781
Soliman, 2013, Growth hormone deficiency in adults with thalassemia: an overview and the I-CET recommendations, Georgian Med News, 222, 79
La Rosa, 2005, Growth hormone secretion in adult patients with thalassaemia, Clin Endocrinol (Oxf), 62, 667, 10.1111/j.1365-2265.2005.02276.x
De Sanctis, 2011, Growth hormone and adrenal response to intramuscular glucagon test and its relationship to IGF-1 production and left ventricular ejection fraction in adult B-thalassemia major patients, Pediatr Endocrinol Rev, 8, 290
Karamifar, 2004, Reduced insulin growth factor I concentrations in iron-overloaded beta thalassaemic patients with normal growth hormone secretion and liver function, Pediatr Endocrinol Rev, 2, 256
De Sanctis, 2014, Insulin-like growth Factor-1 (IGF-1): demographic, clinical and laboratory data in 120 consecutive adult patients with Thalassaemia major, Mediterr J Hematol Infect Dis, 6, e2014074, 10.4084/mjhid.2014.074
De Sanctis, 1999, Clinical experience with growth hormone treatment in patients with beta-thalassaemia major, BioDrugs, 11, 79, 10.2165/00063030-199911020-00002
Scacchi, 2008, Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites, Clin Endocrinol (Oxf), 69, 202, 10.1111/j.1365-2265.2008.03191.x
Sartorio, 2000, Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major, J Endocrinol Invest, 23, 356, 10.1007/BF03343738
Fung, 2010, Nutritional deficiencies in patients with thalassemia, Ann N Y Acad Sci, 1202, 188, 10.1111/j.1749-6632.2010.05578.x
Fung, 2016, The importance of nutrition for health in patients with transfusion-dependent thalassemia, Ann N Y Acad Sci, 1368, 40, 10.1111/nyas.13003
Soliman, 2004, The effect of high-caloric diet on nutritional parameters of children with beta-thalassaemia major, Clin Nutr, 23, 1153, 10.1016/j.clnu.2004.03.001
Claster, 2009, Nutritional deficiencies in iron overloaded patients with hemoglobinopathies, Am J Hematol, 84, 344, 10.1002/ajh.21416
Fung, 2012, Inadequate dietary intake in patients with thalassemia, J Acad Nutr Diet, 112, 980, 10.1016/j.jand.2012.01.017
Fung, 2013, Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial, Am J Clin Nutr, 98, 960, 10.3945/ajcn.112.049221
Morabito, 2002, Bisphosphonates in the treatment of thalassemia-induced osteoporosis, Osteoporos Int, 13, 644, 10.1007/s001980200087
Voskaridou, 2003, Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia, Br J Haematol, 123, 730, 10.1046/j.1365-2141.2003.04657.x
Pennisi, 2003, Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis, J Bone Miner Metab, 21, 402, 10.1007/s00774-003-0435-5
Perifanis, 2004, Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid, Br J Haematol, 125, 91, 10.1111/j.1365-2141.2004.04871.x
Voskaridou, 2006, Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial, Haematologica, 91, 1193
Otrock, 2006, Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial, Ann Hematol, 85, 605, 10.1007/s00277-006-0136-y
Gilfillan, 2006, A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia, Calcif Tissue Int, 79, 138, 10.1007/s00223-006-0314-x
Skordis, 2008, Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major, Pediatr Endocrinol Rev, 6, 144
Leung, 2009, Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits, Hemoglobin, 33, 361, 10.3109/03630260903210377
Chatterjee, 2009, Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment, Hemoglobin, 33, S136, 10.3109/03630260903347898
Toumba, 2010, Osteoporosis syndrome in thalassaemia major: an overview, J Osteoporos, 2010, 537673, 10.4061/2010/537673
D'Eufemia, 2010, Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate, Biomed Pharmacother, 64, 271, 10.1016/j.biopha.2009.06.014
Forni, 2012, Neridronate improves bone mineral density and reduces back pain in beta-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study, Br J Haematol, 158, 274, 10.1111/j.1365-2141.2012.09152.x
Bhardwaj, 2016, Treatment for osteoporosis in people with ß-thalassaemia, Cochrane Database Syst Rev, 3, CD010429
Mamtani, 2010, Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review, Osteoporos Int, 21, 183, 10.1007/s00198-009-0875-4
Chatterjee, 2014, High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major, Br J Haematol, 166, 292, 10.1111/bjh.12833
Voskaridou, 2008, Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis, Acta Haematol, 119, 40, 10.1159/000114869
Canatan, 1995, Effects of calcitonin therapy on osteoporosis in patients with thalassemia, Acta Haematol, 93, 20, 10.1159/000204084
Yassin, 2014, Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis, Indian J Endocrinol Metab, 18, 546, 10.4103/2230-8210.137516
Tournis, 2015, Effects of teriparatide retreatment in a patient with β-thalassemia major, Transfusion, 55, 2905, 10.1111/trf.13237